GGrantIndex
Sort

21,281 grants matching influenza

iPSC-derived macrophages as a model to study the genetic basis of inter-individual variation in immune responses to pathogens

$785,511
Luis Bruno Barreiro · University Of Chicago · R01 · FY2025 · AI

Computational design and development of small protein inhibitors

$785,407
Eva-Maria Strauch · Washington University · R01 · FY2024 · AI

Defining the role of T cell help in germinal centers by intercellular enzymatic labeling

$785,027
Gabriel D Victora · Rockefeller University · R01 · FY2022 · AI

Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness

$785,000
Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2012 · IP

Core_plus Option_A_C_Influenza Surveillance and Vaccine Effectiveness in a Large

$785,000
Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2013 · IP

Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness

$785,000
Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2013 · IP

Core_Prospective population-based estimation of influenza vaccine effectiveness a

$784,995
Michael L Jackson · Kaiser Foundation Health Plan Of Washington · U01 · FY2013 · IP

Core_Prospective population-based estimation of influenza vaccine effectiveness a

$784,980
Lisa A Jackson · Kaiser Foundation Health Plan Of Washington · U01 · FY2011 · IP

Core_Prospective population-based estimation of influenza vaccine effectiveness a

$784,950
Lisa A Jackson · Kaiser Foundation Health Plan Of Washington · U01 · FY2012 · IP

Vaccines to Induce Functional Antibodies Targeting the V2 Loop

$784,933
Susan B Zolla-Pazner · New York University School Of Medicine · P01 · FY2016 · AI

A Diagnostic Microarray for hemorrhagic fever encephalitis viruses

$784,825
David Wang · Washington University · U01 · FY2010 · AI

Generation and Function of NK Cell Memory

$784,741
Ulrich H Von Andrian · Harvard Medical School · R01 · FY2013 · AI

Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza

$784,554
Stefanie N. Vogel · University Of Maryland Baltimore · R01 · FY2013 · AI

Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination

$784,531
Sara Lustigman · New York Blood Center · U01 · FY2017 · AI

Heterosubtypic immunity to influenza virus mediated by MHC-E-restricted memory NK cells

$784,398
Stephanie Jost · Duke University · R01 · FY2022 · AI

Translational Geroscience Network

$784,286
James L. Kirkland · Mayo Clinic Rochester · R33 · FY2023 · AG

Systems investigation of vaccine responses in aging and frailty

$784,057
Albert C Shaw · Yale University · U19 · FY2024 · AI

Enhanced Detection System for Healthcare-Associated Transmission of Infection

$783,939
Lee H. Harrison · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI

A vaccine for genital herpes that achieves sterilizing immunity

$783,564
Harvey Michael Friedman · University Of Pennsylvania · R01 · FY2021 · AI

Anti-Influenza Therapy in Hospitalized Patients with Community-Acquired Pneumonia

$783,522
Julio Alberto Ramirez · University Of Louisville · U18 · FY2010 · IP

Effects of vitamin D and omega-3 fatty acids on infectious diseases and hCAP18

$783,256
Carlos A. Camargo · Brigham And Women'S Hospital · R01 · FY2015 · AI

Monitoring System For Vector-Based Influenza Vaccine

$783,129
Matthew M. Ferris · Indevr, Inc. · R44 · FY2008 · AI

Transcriptomic Signatures of Influenza Vaccine Responses

$782,918
Gregory A. Poland · Mayo Clinic Rochester · R01 · FY2021 · AI

Structural interrogation of vaccine- and infection-induced B cell responses

$782,700
Goran Bajic · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · AI

AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

$782,691
Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2023 · CA